Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22(1):103–14.
Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L’Asparaginase-induced antithrombin III deficiency. Blood. 1994;83(2):386–91.
Article CAS PubMed Google Scholar
Mitchell LG, Halton JM, Vegh PA, Barr RD, Venneri T, Pai KM, et al. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia. Am J Pediatr Hematol Oncol. 1994;16(2):120–6.
Ismail MM, Hamed GM. Activity levels of natural anticoagulant proteins in childhood acute lymphoblastic leukemia: relation to thromboembolic complications and treatment. Blood Coagul Fibrinolysis. 2017;28(1):1–7.
Article CAS PubMed Google Scholar
Biss TT, Payne JH, Hough RE, Grainger JD, Macartney C, Sibson KR, et al. Strategies to prevent and manage thrombotic complications of acute lymphoblastic leukemia in children and young people vary between centers in the United Kingdom. J Pediatr Hematol Oncol. 2016;38(3):221–6.
Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008;50(2):298–303.
Pelland-Marcotte MC, Tole S, Pechlivanoglou P, Brandão LR. Effectiveness and safety of primary thromboprophylaxis in children with cancer: a systematic review of the literature and network meta-analysis. Thromb Haemost. 2019;119(12):2034–42.
Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104(4):756–65.
Article CAS PubMed PubMed Central Google Scholar
Klaassen ILM, Lauw MN, van de Wetering MD, Biemond BJ, Middeldorp S, Abbink FCH, et al. TropicALL study: thromboprophylaxis in children treated for acute lymphoblastic leukemia with low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatr. 2017;17(1):122.
Article PubMed PubMed Central Google Scholar
O’Brien SH, Li D, Mitchell LG, Hess T, Zee P, Yee DL, et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric Acute Lymphoblastic Leukaemia (ALL)-rationale and design. Thromb Haemost. 2019;119(5):844–53.
Mall V, Thomas KB, Sauter S, Niemeyer CM, Sutor AH. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr. 1999;211(4):205–10.
Article CAS PubMed Google Scholar
Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390–401.
Article CAS PubMed Google Scholar
Ishihara T, Nogami K, Ochi S, Ishida T, Kosaka Y, Sawada A, et al. Disordered hemostasis associated with severely depressed fibrinolysis demonstrated using a simultaneous thrombin and plasmin generation assay during L-asparaginase induction therapy in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(1): e28016.
Article CAS PubMed Google Scholar
Risseeuw-Appel IM, Dekker I, Hop WC, Hählen K. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study. Med Pediatr Oncol. 1994;23(4):335–43.
Article CAS PubMed Google Scholar
Mitchell LG, Andrew M, Hanna K, Abshire T, Halton J, Anderson R, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) study. Cancer. 2003;97(2):508–16.
Article CAS PubMed Google Scholar
Ghanem KM, Dhayni RM, Al-Aridi C, Tarek N, Tamim H, Chan AKC, Saab R, Abboud MR, El-Solh H, Muwakkit SA. Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatr Blood Cancer. 2017;64(12). https://doi.org/10.1002/pbc.26694. Epub 2017 Jun 29.
Gidl A, Füreder A, Benesch M, Dworzak M, Engstler G, Jones N, et al. Incidence and risk factors of venous thromboembolism in childhood acute lymphoblastic leukaemia - a population-based analysis of the Austrian Berlin-Frankfurt-Münster (BFM) study group. Pediatr Hematol Oncol. 2023;40(2):181–91.
Article CAS PubMed Google Scholar
Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost. 2008;100(2):330–7.
Prasca S, Carmona R, Ji L, Ko RH, Bhojwani D, Rawlins YA, et al. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018;165:44–50.
Article CAS PubMed PubMed Central Google Scholar
Rank CU, Lynggaard LS, Als-Nielsen B, Stock W, Toft N, Nielsen OJ, et al. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2020;10(10):Cd013399.
Halton JM, Mitchell LG, Vegh P, Eves M, Andrew ME. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase. Am J Hematol. 1994;47(3):157–61.
Article CAS PubMed Google Scholar
Klaassen ILM, Zuurbier CCM, Hutten BA, van den Bos C, Schouten AYN, Stokhuijzen E, et al. Venous thrombosis in children with acute lymphoblastic leukemia treated on DCOG ALL-9 and ALL-10 protocols: the effect of fresh frozen plasma. TH Open. 2019;3(2):e109–16.
Article PubMed PubMed Central Google Scholar
Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2001;12(5):367–70.
Article CAS PubMed Google Scholar
Nowak-Göttl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol. 1996;56(1–2):35–8.
Pelland-Marcotte MC, Amiri N, Avila ML, Brandão LR. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children. Cochrane Database Syst Rev. 2020;6(6):Cd005982.
Czogała M, Balwierz W, Sztefko K, Rogatko I. Antithrombin III as the indicator of L-asparaginase activity in children treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39(2):114–20.
留言 (0)